Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Capital Leases (2019 - 2021)

Historic Capital Leases for Fulcrum Therapeutics (FULC) over the last 3 years, with Q4 2021 value amounting to $2.6 million.

  • Fulcrum Therapeutics' Capital Leases fell 1537.2% to $2.6 million in Q4 2021 from the same period last year, while for Dec 2021 it was $2.6 million, marking a year-over-year decrease of 1537.2%. This contributed to the annual value of $2.6 million for FY2021, which is 1537.2% down from last year.
  • Per Fulcrum Therapeutics' latest filing, its Capital Leases stood at $2.6 million for Q4 2021, which was down 1537.2% from $2.7 million recorded in Q3 2021.
  • In the past 5 years, Fulcrum Therapeutics' Capital Leases registered a high of $3.8 million during Q2 2019, and its lowest value of $2.6 million during Q4 2021.
  • For the 3-year period, Fulcrum Therapeutics' Capital Leases averaged around $3.2 million, with its median value being $3.2 million (2020).
  • Its Capital Leases has fluctuated over the past 5 years, first plummeted by 1251.33% in 2020, then tumbled by 1537.2% in 2021.
  • Quarter analysis of 3 years shows Fulcrum Therapeutics' Capital Leases stood at $3.5 million in 2019, then fell by 13.35% to $3.1 million in 2020, then decreased by 15.37% to $2.6 million in 2021.
  • Its Capital Leases stands at $2.6 million for Q4 2021, versus $2.7 million for Q3 2021 and $2.8 million for Q2 2021.